
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.369003690037 | 2.71 | 2.8396 | 2.59 | 79311 | 2.70299511 | CS |
4 | -0.2799 | -9.39293264875 | 2.9799 | 3.02 | 2.35 | 145076 | 2.72997098 | CS |
12 | 0.26 | 10.6557377049 | 2.44 | 3.395 | 2.35 | 220804 | 2.85940473 | CS |
26 | -0.5 | -15.625 | 3.2 | 3.395 | 2.22 | 224664 | 2.83366357 | CS |
52 | -1.41 | -34.3065693431 | 4.11 | 5.74 | 2.22 | 186975 | 3.41895044 | CS |
156 | -33.6 | -92.5619834711 | 36.3 | 53.7 | 1.62 | 2952895 | 6.7872564 | CS |
260 | -8.7 | -76.3157894737 | 11.4 | 106.5 | 1.62 | 2496673 | 21.56045013 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.